Emblation Appoints Medical Affairs Advisors

October 6, 2026

STIRLING, Scotland and LINCOLN, R.I., 6 October, 2026 — Emblation, the company behind the innovative SwiftPro® microwave therapy system, today announced the appointment of four Medical Affairs Advisors, bringing together distinguished clinicians and podiatry experts who will contribute their experience and perspectives to the company’s clinical education initiatives for its SwiftPro® medical device. SwiftPro recently received FDA 510(k) clearance for the treatment of common and plantar warts.

“We are delighted to have the opportunity to collaborate with these distinguished clinicians,” said Ian Stevens, Chief Executive Officer of Emblation. “Their expertise and experience will be invaluable as we continue to expand peer-to-peer educational initiatives and support the effective use of SwiftPro.” 

Unlike traditional wart treatments that damage or surgically remove infected tissue, SwiftPro uses HeatBeat™ microwave therapy to alert the body’s immune system to the viral infection, helping it recognize and fight the virus naturally. As the immune response clears the underlying viral infection, the associated skin lesion is resolved as well. By contrast, traditional treatments physically destroy or excise the wart, but do so without eliminating the underlying virus, which can contribute to recurrence. 

The Medical Affairs Advisors will facilitate peer-to-peer educational support, providing clinical perspectives and practical insights to help clinicians optimize their use of SwiftPro. Guidance will also be provided on the use of Swiftscope™, the companion app that enables enhanced visualization, treatment documentation and monitoring of patient progress. 

Ivan Bristow, PhD (Dermatol), MSc (Oxon), FRCPodM is an internationally recognized podiatrist, academic, and author based in the United Kingdom, with expertise in podiatric dermatology and skin conditions affecting the lower limb and foot. Dr. Bristow has published more than 140 professional and academic papers and has authored textbooks on foot and ankle disorders. He also leads the Podiatric Dermatology Blog. His current work includes consultancy, research, and private practice. He is an Honorary Professor at Health Sciences University in Dorset, United Kingdom, and holds visiting positions at universities in the UK and Australia. 

Robert M. Conenello, DPM is founder of Orangetown Podiatry in New York, where he specializes in sports medicine, lower extremity biomechanics and regenerative medicine. He frequently lectures globally on biomechanics and regenerative medicine. A past President of the American Academy of Podiatric Sports Medicine, Dr. Conenello has extensive experience in non-invasive and innovative treatment approaches and is committed to advancing effective, patient-focused care. 

Melissa J. Lockwood, DPM is the founder of Heartland Foot and Ankle Associates, P.C. in Illinois and a podiatric physician and surgeon with extensive experience treating dermatologic conditions of the foot. A nationally recognized speaker on podiatric medicine, Dr. Lockwood is a Fellow and current Chairperson of the American Society of Podiatric Surgeons (ASPS). Her clinical interests include innovative, non-invasive treatment approaches, with a particular focus on dermatological conditions and preventive care. 

Tracey C. Vlahovic, DPM is a podiatric physician, clinical professor, and author with extensive experience in podiatric dermatology. Dr. Vlahovic practices at Bay Area Foot Care in San Francisco and currently is professor at Samuel Merritt University College of Podiatric Medicine in Oakland. An international speaker and author, Dr. Vlahovic has published more than 90 peer-reviewed papers addressing lower extremity dermatology, plantar warts, dermoscopy, and nail disorders. 

About Emblation
Based in Stirling, Scotland with U.S. headquarters in Lincoln, R.I., Emblation launched Swift in 2016. Since then, over 750,000 treatments have been conducted globally with over 85% of patients experiencing complete resolution and a low recurrence rate compared to traditional methods. The company recently received FDA 510(k) clearance for expanded indications of its Swift and SwiftPro Systems for the treatment of common and plantar warts.  

Media Contact:
Emblation
844-793-8776
media@emblation.com